Maren Dirnberger‐Hertweck

Tafasitamab plus lenalidomide in relapsed or refractory diffuse large B-cell lymphoma (L-MIND): a multicentre, prospective, single-arm, phase 2 study

Gilles Salles, Johannes Duell, Eva González‐Barca et al. · The Lancet Oncology · 2020 · 519 citations · Full text

Medicine, Oncology, Pharmacotherapy +10

Long-term outcomes from the Phase II L-MIND study of tafasitamab (MOR208) plus lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma

Johannes Duell, Kami J. Maddocks, Eva González‐Barca et al. · Haematologica · 2021 · 140 citations · Full text

Medicine, Oncology, Pharmacotherapy +12

Phase IIa study of the CD19 antibody MOR208 in patients with relapsed or refractory B-cell non-Hodgkin’s lymphoma

Wojciech Jurczak, Pier Luigi Zinzani, Gianluca Gaïdano et al. · Annals of Oncology · 2018 · 132 citations · Full text

Medicine, Hematology, Oncology +16

Randomized phase 1b trial of MOR103, a human antibody to GM-CSF, in multiple sclerosis

Cris S. Constantinescu, Aliya Asher, Waldemar Fryze et al. · Neurology Neuroimmunology & Neuroinflammation · 2015 · 105 citations · Full text

Pharmacy, Clinical Pharmacokinetics, Neurology +17

A Phase IIa, Open-Label, Multicenter Study of Single-Agent Tafasitamab (MOR208), an Fc-Optimized Anti-CD19 Antibody, in Patients with Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma: Long-Term Follow-up, Final Analysis

Wojciech Jurczak, Pier Luigi Zinzani, Gianluca Gaïdano et al. · Blood · 2019 · 26 citations

Life Sciences, Immunology, Oncology +13